DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for peripheral vascular disease — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePeripheral vascular disease maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for peripheral vascular disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
The 1992 editorial states that most patients with intermittent claudication are treated conservatively, with smoking cessation and exercise therapy as the foundation. It notes that various drug classes are widely prescribed for peripheral vascular disease, and claims that medical treatment aims to improve functional capability, inhibit progression of atherosclerotic lesions, or reduce cardiac and cerebrovascular morbidity and mortality. The editorial provides guidelines for future well-controlled trials of new drugs, implying that existing evidence for drug efficacy was not yet conclusive at that time.
A 1952 article by Goodwin in the British Medical Bulletin is titled "Medical Treatment of Peripheral Vascular Disease: The Pharmacological Approach" but no data on specific drugs, response rates, or survival are provided in the citation. A 2018 book titled "Peripheral Arterial Disease - A Practical Approach" summarises diagnostic testing, therapeutic interventions, and innovations but offers no numerical outcomes. A 2017 review of combination therapy for complex peripheral artery disease states that current-generation devices leave "ample room for improvement" and that there is a "paucity of high-level evidence" to direct treatment, with many forms of combination therapy under investigation and little clinical research coordination.
A 2023 supplemental file on patient knowledge and preferences for peripheral artery disease treatment provides no clinical outcomes, survival data, or response rates. Across all these abstracts, no concrete numbers for survival, functional improvement, or lesion regression are reported. What is still missing are adequately powered, well-controlled trials that can demonstrate whether any drug or combination device regimen improves walking distance, reduces amputation, or lowers cardiovascular events in a reproducible way.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Heart Journal · 1992 · 13 citations
Medical treatment of peripheral vascular disease: good or bad?
AbstractThe majority of patients with intermittent claudication are treated conservatively; smoking must be stopped and exercise therapy commenced. There are various classes of drugs that are widely prescribed for the treatment of peripheral vascular disease. In this editorial the medical treatment of peripheral vascular disease is claimed to achieve at least one of three goals: (1) improvement of the functional capability; (2) inhibition of the progression of the atherosclerotic and anatomical lesions; (3) reduction of the cardiac and cerebrovascular morbidity and mortality. Guidelines are given for well controlled trials for newly developed drugs for the treatment of peripheral vascular disease in the future.
MEDICAL TREATMENT OF PERIPHERAL VASCULAR DISEASE: The Pharmacological Approach
AbstractJournal Article MEDICAL TREATMENT OF PERIPHERAL VASCULAR DISEASE: The Pharmacological Approach Get access J.F. GOODWIN, M.D. M.R.C.P J.F. GOODWIN, M.D. M.R.C.P Professor and Lecturer Department of Medicine postgraduate Medical School of London Search for other works by this author on: Oxford Academic PubMed Google Scholar British Medical Bulletin, Volume 8, Issue 4, 1952, Pages 371–374, https://doi.org/10.1093/oxfordjournals.bmb.a074205 Published: 01 April 1952
Peripheral Arterial Disease - A Practical Approach
Abstract"Peripheral Arterial Disease - A Practical Approach" is an honest effort to provide a clinically relevant approach to the management plan in patients presenting with peripheral vascular symptoms. We have summarized the most pertinent practical aspects of peripheral vascular disease, their clinical implications, diagnostic testing, therapeutic interventions and innovations. We hope this book serves as a reference for basic and advanced peripheral vascular care.
The Journal of Cardiovascular Surgery · 2017 · 2 citations
Combination therapy for complex peripheral artery disease: the evidence for combining mechanical revascularization with anti-restenotic drug delivery systems
AbstractThe management of complex, lower-extremity peripheral artery disease remains a difficult challenge, with ample room for improvement in the results seen with current generation devices. Therapies which use a combination of multiple devices for their mechanical and anti-restenotic properties may be advantageous, and offer an opportunity to improve the durability of revascularization through optimizing and individualizing care. Combination therapy typically utilizes drug delivery devices in addition to stents and atherectomy to achieve improved results. However, there is a paucity of high-level evidence with which to direct treatment, with many different forms of combination therapy under investigation and little clinical research coordination. Herein we seek to describe and evaluate the growing number of options for combination treatment in this challenging disease.
sj-pdf-1-vmj-10.1177_1358863X231181613 – Supplemental material for Patient knowledge and preferences for peripheral artery disease treatment
AbstractSupplemental material, sj-pdf-1-vmj-10.1177_1358863X231181613 for Patient knowledge and preferences for peripheral artery disease treatment by Kim G Smolderen, Gaëlle Romain, Kensey Gosch, Ahmad Arham, Jeremy B Provance, John A Spertus, Anwesh B Poosala, Mehdi H. Shishehbor, David Safley, Kate Scott, Nancy Stone and Carlos Mena-Hurtado in Vascular Medicine
Training fútbol: Revista técnica profesional · 2006 · 0 citations
20 maneras de mantener cohesionado a un equipo
AbstractSunitinib-induced thrombotic microangiopathy (TMA) is a secondary TMA caused by sunitinib. Despite the extensive use of sunitinib in patients with renal cell carcinoma and other malignancies, little is known about this complication of sunitinib. No clinical trials of sunitinib have studied this complication in any group of patients. We here review the normal physiology of vascular endothelial growth factor in the kidney, and discuss the pathogenesis, clinical and laboratory manifestations, pathological changes in the kidney, and the management of this uncommon complication of sunitinib.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
